drugset / Trial / NCT04317092

Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)

NCT04317092

Phase 2 Unknown 402 enrolled National Cancer Institute, Naples
NaSingle-groupOpen-labelTreatment

Summary

This study project includes a single-arm phase 2 study and a parallel cohort study, enrolling patients with COVID-19 pneumonia.

Timeline

Start
2020-03-19
Primary completion
2023-12-19
Completion
2023-12-19

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tocilizumab Monoclonal antibody 8 mg/kg Intravenous

Indications